05124nam 2200625Ia 450 991083094390332120180718155010.01-282-46085-497866124608523-527-62684-03-527-62683-2(CKB)1000000000802822(EBL)482029(OCoLC)566133558(SSID)ssj0000341344(PQKBManifestationID)11257586(PQKBTitleCode)TC0000341344(PQKBWorkID)10389901(PQKB)10691824(MiAaPQ)EBC482029(PPN)152509879(EXLCZ)99100000000080282220090506d2009 uy 0engur|n|---|||||rdacontentrdamediardacarrierPeptides as drugs[electronic resource] discovery and development /edited by Bernd GronerWeinheim Wiley-VCHc20091 online resource (244 p.)Description based upon print version of record.3-527-32205-1 Includes bibliographical references and index.Peptides as Drugs; Contents; Preface; List of Contributors; 1: Peptides as Drugs: Discovery and Development; 1.1 Discovery of New Potential Drug Targets and the Limitations of Druggability; 1.2 Protein Interaction Domains Are at the Core of Signaling Pathways; 1.3 Peptides as Inhibitors of Protein Interactions; References; 2: Mimics of Growth Factors and Cytokines; 2.1 Introduction; 2.2 The Cytokines; 2.2.1 The Receptors; 2.2.2 "Simple" Receptors; 2.2.3 "Complex" Receptors; 2.3 Defining Receptor Recognition Sites in Cytokines Using Chimeric Proteins2.4 Receptor Recognition Sites are Organized as Exchangeable Modules2.5 The Concept of Fusing the Cytokine to the Soluble Receptor: Hyper-IL-6; 2.6 Antagonists Specifically Inhibiting IL-6 Trans-Signaling; 2.7 In Vitro Evolution of Peptides and Proteins; 2.7.1 Platforms for the Selection of High-Affinity Binders; 2.7.2 Agonists and Antagonists of Cytokines and Growth Hormones; 2.8 Concluding Remarks; References; 3: Peptides Derived from Exon v6 of the CD44 Extracellular Domain Prevent Activation of Receptor Tyrosine Kinases and Subsequently Angiogenesis and Metastatic Spread of Tumor Cells3.1 Introduction3.2 CD44 Proteins and Their Involvement in RTK Activation; 3.3 CD44v6 Acts as a Coreceptor for c-Met and Ron; 3.4 Three Amino Acids in CD44 Exon v6 Are Crucial for the CD44v6 Coreceptor Function, and Small Peptides Can Interfere with This Function; 3.5 The Ectodomain of CD44v6 Binds to HGF; 3.6 Peptides Corresponding to Exon v6 of CD44 Inhibit Metastatic Spread of Tumor Cells; 3.7 The Significance of the Collaboration between CD44v6 and c-Met In Vivo; 3.8 The CD44v6 Peptides Interfere with Angiogenesis; 3.9 Outlook; References4: Peptide Aptamers Targeting the Viral E6 Oncoprotein Induce Apoptosis in HPV-positive Cancer Cells4.1 Human Papillomaviruses and Oncogenesis; 4.1.1 Cervical Cancer; 4.1.2 The E6 and E7 Genes; 4.2 Peptide Aptamers Targeting the HPV E6 Oncoprotein; 4.3 E6-Targeting Peptide Aptamers: Therapeutic Perspectives; 4.3.1 Therapeutic Target Protein Evaluation by Peptide Aptamers; 4.3.2 The Intrinsic Therapeutic Potential of Peptide Aptamers; 4.3.3 Identification of Functional Peptide Mimics by Displacement Screening; 4.4 Perspectives; References5: The Prevention of HIV Infection with Viral Entry Inhibitors5.1 Introduction: The Potential of Peptides as Drugs in the Treatment of HIV Infection; 5.2 The HIV Entry Process; 5.3 Peptides that Inhibit Receptor or Coreceptor Binding; 5.3.1 Physiological Antimicrobial Peptides; 5.3.1.1 Defensins; 5.3.2 Chemokines; 5.3.3 Synthetic Peptides and Peptidomimetics; 5.4 Inhibitors of the Viral and Cellular Membrane Fusion Process; 5.5 Entry Inhibitory Peptides Selected by the Phage Display Technology; 5.6 Limitations of Peptides in the Treatment of HIV Infection5.7 Strategies to Prolong the In Vivo Half-Life of Antiviral PeptidesBy covering the full spectrum of topics relevant to peptidic drugs, this timely handbook serves as an introductory reference for both drug developers and biomedical researchers interested in pharmaceutically active peptides, presenting both the advantages and challenges associated with this molecular class.The first part discusses current approaches to developing pharmaceutically active peptides, including case studies of the use of peptidic drugs in cancer and AIDS therapy. The second part surveys strategies for the development and targeting of peptidic drugs.With its integration of bDrugsDesignPeptide drugsDrugsDesign.Peptide drugs.615.19615.3Groner B(Bernd)1709299MiAaPQMiAaPQMiAaPQBOOK9910830943903321Peptides as drugs4098954UNINA04142nam 22007815 450 991048321820332120200713014455.03-658-12721-X10.1007/978-3-658-12721-3(CKB)3710000000627557(EBL)4460325(SSID)ssj0001654079(PQKBManifestationID)16433418(PQKBTitleCode)TC0001654079(PQKBWorkID)14982146(PQKB)10880755(DE-He213)978-3-658-12721-3(MiAaPQ)EBC4460325(PPN)192771256(EXLCZ)99371000000062755720160329d2016 u| 0gerur|n|---|||||txtccrLeistungsanreize in der Transportlogistik Entwicklung und Simulation aus Perspektive der Prinzipal-Agent-Theorie /von Marcus Müller1st ed. 2016.Wiesbaden :Springer Fachmedien Wiesbaden :Imprint: Springer Vieweg,2016.1 online resource (337 p.)ResearchDescription based upon print version of record.3-658-12720-1 Includes bibliographical references.Transportlogistik im Erdbau -- Die Prinzipal-Agent-Theorie als Bezugsrahmen -- Gestaltung und Simulation des Anreizsystems.Marcus Müller beschreibt und erläutert Zielkonflikte zwischen Bauleitung und Baugeräteführer und stellt ein Modell auf, das Prognosen zur Wirkung von Anreizsystemen treffen kann. Aus der Theorie und Anwendungsdomäne leitet der Autor Anforderungen ab, um die Frage nach der Gestaltung von Anreizsystemen zu beantworten, mit dem Ziel, Transportleistungen zu erhöhen. Seine Studie bestätigt die experimentellen bzw. empirischen Erkenntnisse zur Wirkung von Anreizsystemen und zeigt, dass diese auch für Transportlogistiksysteme im Tiefbau gelten. Aus den Erkenntnissen der Simulation leitet der Autor Empfehlungen für die Gestaltung von Entlohnungsmodellen ab. Der Inhalt Transportlogistik im Erdbau Die Prinzipal-Agent-Theorie als Bezugsrahmen Gestaltung und Simulation des Anreizsystems Die Zielgruppen Dozierende und Studierende der Fachgebiete Baubetriebslehre, BWL, Wirtschaftsinformatik Praktiker des Fachgebiets Baumanagement Der Autor Dr. Marcus Müller promovierte bei Univ.-Prof. Dr. Stefan Kirn am Lehrstuhl für Wirtschaftsinformatik 2 der Universität Hohenheim und leitete Forschungsprojekte mit dem Schwerpunkt Baulogistik. Er arbeitet derzeit als .Building—SuperintendenceConstruction industry—ManagementBuildingSuperintendenceEngineering geologyEngineering—GeologyFoundationsHydraulicsBusiness logisticsManagement information systemsConstruction Managementhttps://scigraph.springernature.com/ontologies/product-market-codes/T23039Geoengineering, Foundations, Hydraulicshttps://scigraph.springernature.com/ontologies/product-market-codes/T23020Logisticshttps://scigraph.springernature.com/ontologies/product-market-codes/519020Business Information Systemshttps://scigraph.springernature.com/ontologies/product-market-codes/522030Building—Superintendence.Construction industry—Management.BuildingSuperintendence.Engineering geology.Engineering—Geology.Foundations.Hydraulics.Business logistics.Management information systems.Construction Management.Geoengineering, Foundations, Hydraulics.Logistics.Business Information Systems.620Müller Marcusauthttp://id.loc.gov/vocabulary/relators/aut632458BOOK9910483218203321Leistungsanreize in der Transportlogistik2848510UNINA